MOVE Stock Analysis: Medacta | SW

Medical Devices | SW, Switzerland | Market Cap: 2.186m CHF | 12M Return: -26.1% | CH0468525222 | Charts, Fundamentals & Technical Analysis

Hip Implants, Knee Replacement, Shoulder Prostheses, Spinal Devices
Total Rating 33
Safety 81
Buy Signal -0.51
Health Care Equipment
Sub-Industry Rotation: -7.0
Market Cap: 2.62B
Avg Turnover: 3.24M
Risk 3d forecast
Volatility57.0%
VaR 5th Pctl9.41%
VaR vs Median0.28%
Reward TTM
Sharpe Ratio-0.90
Rel. Str. IBD9.4
Rel. Str. Peer Group10.5 pctl
Character TTM
Beta0.302
Beta Downside0.374
Hurst Exponent0.496
Choppyness68.5%
Drawdowns 3y
Max DD39.08%
CAGR/Max DD0.00
CAGR/Mean DD0.00

Warnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 7.6 years of data, until 10/2026

Jan +6.7% 11
Feb -1.8% 11
Mar -4.5% 60
Apr +4.3% 11
May +1.4% 5
Jun -2.2% 5
Jul +3.0% 38
Aug -1.9% 18
Sep -1.9% 38
Oct +0.8% 5
Nov +3.4% 11
Dec -0.5% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: MOVE Medacta

Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical devices across the Americas, Asia-Pacific, and the Middle East and Africa. Its offerings include personalized 3D planning tools for joint replacement, sports medicine, and spine surgery. The Swiss health care equipment company was founded in 1958 and is headquartered in Castel San Pietro.

Headlines to Watch Out For
  • Hip and knee implant demand drives procedure-led revenue growth
  • NextAR adoption and surgeon training support share gains
  • Salesforce expansion boosts growth but pressures near-term margins
Piotroski VR-10 (Strict) 5.5
Net Income: 77.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.00 > 0.02 and ΔFCF/TA -3.33 > 1.0
NWC/Revenue: 36.94% < 20% (prev 39.87%; Δ -2.94% < -1%)
CFO/TA 0.13 > 3% & CFO 134.6m > Net Income 77.1m
Net Debt (343.9m) to EBITDA (191.3m): 1.80 < 3
Current Ratio: 2.10 > 1.5 & < 3
Outstanding Shares: last quarter (20.0m) vs 12m ago 0.06% < -2%
Gross Margin: 62.46% > 18% (prev 67.61%; Δ -5.15% > 0.5%)
Asset Turnover: 75.51% > 50% (prev 75.06%; Δ 0.45% > 0%)
Interest Coverage Ratio: 17.52 > 6 (EBIT TTM 109.1m / Interest Expense TTM 6.23m)
Altman Z'' 4.90
A: 0.26 (Total Current Assets 497.6m - Total Current Liabilities 236.6m) / Total Assets 1.01b
B: 0.45 (Retained Earnings 452.2m / Total Assets 1.01b)
C: 0.12 (EBIT TTM 109.1m / Avg Total Assets 935.8m)
D: 0.92 (Book Value of Equity 484.6m / Total Liabilities 526.2m)
Altman-Z'' = 4.90 = AAA
Beneish M -2.83
DSRI: 1.09 (Receivables 139.7m/117.5m, Revenue 706.6m/646.1m)
GMI: 1.08 (GM 67.61% / 62.46%)
AQI: 0.98 (AQ_t 0.09 / AQ_t-1 0.09)
SGI: 1.09 (Revenue 706.6m / 646.1m)
TATA: -0.06 (NI 77.1m - CFO 134.6m) / TA 1.01b)
Beneish M = -2.83 (Cap -4..+1) = A
What is the price of MOVE shares?

As of November 12, 2026, the stock is trading at CHF 110.00 with a total of 28,984 shares traded. Over the past week, the price has changed by -11.29%, over one month by -3.68%, over three months by -17.54% and over the past year by -26.10%.

Current recommended Stop Loss: 104.80 (which is 4.7% or 1.3 ATR below the current price).

Is MOVE a buy, sell or hold?

Medacta has no consensus analysts rating.

Medacta (MOVE) - Fundamental Data Overview as of 12 November 2026
Market Cap USD = 2.62b (2.19b CHF * 1.2003 CHF.USD)
Market Cap EUR = 2.37b (2.19b CHF * 1.082200050354 CHF.EUR)
P/E Trailing = 30.9605
P/E Forward = 30.7692
P/S = 3.0884
P/B = 4.882
Revenue TTM = 706.6m EUR
EBIT TTM = 109.1m EUR
EBITDA TTM = 191.3m EUR
Long Term Debt = 158.7m EUR (from longTermDebt, last quarter)
Short Term Debt = 117.0m EUR (from shortTermDebt, last quarter)
Debt = 380.0m EUR (from shortLongTermDebtTotal, last quarter) + Leases 58.4m
Net Debt = 343.9m EUR (calculated: Debt 380.0m - CCE 36.1m)
Enterprise Value = 2.71b EUR (2.37b + Debt 380.0m - CCE 36.1m)
Interest Coverage Ratio = 17.52 (Ebit TTM 109.1m / Interest Expense TTM 6.23m)
EV/FCF = -1000.0x (Enterprise Value 2.71b / FCF TTM -1.85m)
FCF Yield = -0.07% (FCF TTM -1.85m / Enterprise Value 2.71b)
FCF Margin = -0.26% (FCF TTM -1.85m / Revenue TTM 706.6m)
Net Margin = 10.92% (Net Income TTM 77.1m / Revenue TTM 706.6m)
Gross Margin = 62.46% ((Revenue TTM 706.6m - Cost of Revenue TTM 265.2m) / Revenue TTM)
Gross Margin QoQ = 65.24% (prev 59.48%)
Tobins Q-Ratio = 2.68 (Enterprise Value 2.71b / Total Assets 1.01b)
Interest Expense / Debt = 1.64% (Interest Expense 6.23m / Debt 380.0m)
Taxrate = 21.12% (20.7m / 97.8m)
NOPAT = 86.1m (EBIT 109.1m * (1 - 21.12%))
Current Ratio = 2.10 (Total Current Assets 497.6m / Total Current Liabilities 236.6m)
Debt / Equity = 0.78 (Debt 380.0m / totalStockholderEquity, last quarter 484.6m)
Debt / EBITDA = 1.80 (Net Debt 343.9m / EBITDA 191.3m)
 Debt / FCF = -186.0 (out of range, set to none) (Net Debt 343.9m / FCF TTM -1.85m)
 Total Stockholder Equity = 436.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.24% (Net Income 77.1m / Total Assets 1.01b)
RoE = 17.68% (Net Income TTM 77.1m / Total Stockholder Equity 436.3m)
RoCE = 18.34% (EBIT 109.1m / Capital Employed (Equity 436.3m + L.T.Debt 158.7m))
RoIC = 10.06% (NOPAT 86.1m / Invested Capital 855.9m)
WACC = 5.92% (E(2.37b)/V(2.75b) * Re(6.66%) + D(380.0m)/V(2.75b) * Rd(1.64%) * (1-Tc(0.21)))
Discount Rate = 6.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 1.18 | Cagr: -0.11%
 [DCF] Fair Price = unknown (Cash Flow -1.85m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.14 | Revenue CAGR: 14.70% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=4.75 | Chg30d=-0.20% | Revisions=-50% | GrowthEPS=+9.6% | GrowthRev=+11.0%
EPS next Year (2027-12-31): EPS=5.63 | Chg30d=-0.72% | Revisions=-50% | GrowthEPS=+18.5% | GrowthRev=+12.6%
[Analyst] Revisions Ratio: -67% (up=0, down=6)